Ironwood Pharmaceuticals Inc 뉴스 - IRWD | 주식 나스닥

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

Form 4 - Statement of changes in beneficial ownership of securities

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

– New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

– Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with...

Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens JMP Life...

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure (SBS-IF) accepted as late-breaker oral presentation on...

ProLiberty 4 월 전

Possible buy below $5? Any chance the VectivBio acquisition ends up not being as horrible as it currently appears? When might the acquired asset begin to generate revenue?

sold...
fast trading.

👍️0

philaya 9 월 전

Using radar...
Got this today

👍️0

Dubster watching 9 월 전

B$9.01

👍️0

BabySealHugger 4 년 전

Hearing rumblings of IRWD this week. Anyone else?

👍️0

whytestocks 4 년 전

Just In: $IRWD Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Trans...

Find out more IRWD - Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript

👍️0

whytestocks 4 년 전

Just In: $IRWD Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

– Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or near...

In case you are interested IRWD - Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

👍️0

whytestocks 5 년 전

News: $IRWD Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

– Phase IIIb study met all primary and secondary endpoints with statistical significance and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C – – Results further support the efficacy and s...

Got this from https://marketwirenews.com/news-releases/ironwood-and-allergan-report-positive-topline-data-from-phase-iiib-trial-of-linzess-xae-linaclotide-in-adults-with-irritable-bowel-syndrome-with-constipation-ibs-c--8377600.html

👍️0

ClayTrader 6 년 전

* * $IRWD Video Chart 05-17-2019 * *

Link to Video - click here to watch the technical chart video

👍️0

stocktrademan 6 년 전

IRWD buy 11.365

https://www.ironwoodpharma.com/

normal chart

log chart

👍️0

chemist99 6 년 전

epilogue

SGYP down to 3 pennies after hours today

the signs were all there, but you had to be willing to read them.

if there is a list somewhere, like, "always go on the opposite end of the trade for all recommendations from these institutions" - most of the SGYP institutional investors should definitely be on it IMHO.

👍️0

chemist99 6 년 전

How did that work out for you;)

👍️0

chemist99 7 년 전

knew all too well what was going on behind the Synergy scenes;

http://www.nj.com/business/index.ssf/2012/08/bristol-myers_drug_flop_erases.html

if you make a multinational company lose a couple billion $ in short order & leave them stuck with trial deaths, AND expect anyone in the pharmaceutical industry ever to trust you again, you need to have your head examined imo. he's probably looking under his car every morning...

there's a really nice package deal available for you though from the experienced crew, if you're still game for it:

Synergy, $6 in January, now on sale at $1.90, Trovagene, went public at $24, now marked down to 51 cents for quick clearance, and ContraVir, $5 as recently as 2015, but now available for just 49 cents! Yes, you get all three of these made-to-be-sold companies for just $2.90! And, if you act now, we'll throw in 10 shares of Callisto Pharmaceuticals, a company which sank beneath the waves with Cap'n Gary at the helm!

👍️0

chemist99 7 년 전

Enjoy the front row seat to the final act of the drama, sure was expensive enough...

https://seekingalpha.com/article/4089539-ironwood-will-press-good-fight-gerd

I did 10,000 shares on that one, didn't get in at the low, but out close to the top. Flipped it into sgyp in the low 3's

👍️0

chemist99 9 년 전

thanks for bringing it to my attention! that was nice, ~7.30s to $10.24 in less than a month, 30+% !
Hope you didn't miss it :) ?

👍️0

brownsfan407 9 년 전

you were right, we saw 7's this week. 52 week low

👍️0

chemist99 9 년 전

SGYP short volume 25 million plus now...looks like the hedgefunds are in the business to lose money then ?

👍️0

brownsfan407 9 년 전

under 10 coming your way soon. the trend is your friend

👍️0

brownsfan407 9 년 전

IRWD, 10.71 new 52 week low fact, not rant
8.00 in September lows

👍️0

chemist99 9 년 전

no pain data, skewed side effect profile = no partner IMO.

no partner = slim chance, if any, of competing in the marketplace for a primary care drug with an army of people promoting the first-to-market competitor, IMO.

simple as that.

rant all you want. doesn't change the fact that Phase III CIC data are out - and still no buyout & no partnership despite the "hey we're for sale" press article LOL.

that, and the low (~30%) institutional ownership of SGYP compared with IRWD (~100%), combined with the ~22 mill. short volume for SGYP speak volumes...

👍️0

brownsfan407 9 년 전

IRWD pennies of 51 week low, while market booms. Stock price heading in the same direction as the diarrhea it causes. despite misinformation by IRWD propagandist.. BTW, I bought a boatload of warrants at .36, now 4.00. I can be very patient for the next explosion. 2 phase 3 results and an NDA by year end

👍️0

brownsfan407 9 년 전

from an IRWD board? nice, just a little biased. Don't try to be naïve, you have no idea what is going on behind the scenes. and like I said you have lots of holders, but yahoo stats says 3 percent own over 5 percent, and that 3 percent includes insider holdings. Everyone owns a little. Cerrone TOOK 1/2 year with inhibitex, to get top buck, we have only been a month here. 4 catalysts by year end. we are up 165 percent, you? your short at 4 dollars is a FAILED trade

👍️0

chemist99 9 년 전

sooner or later the Wall Street hysteria, fanned by a couple of hyperbolic analyst op ed pieces, will be over; - the music will stop, people will wake up & valuations will adjust to reality. they always do.

I quote a comment of someone from "the trenches" posted on the IRWD CP board, who puts it in quite simple (& blunt) terms:

anonymous, Jul 22, 2015 at 9:37 AM
(quote) ...." Less diarrhea, yes but with that is less efficacy. You can't treat cic with no diarrhea and have the same efficacy. So you think you can hire a third of the reps ? So roughly 1 rep per state to grow the constipation market of 50 million? This is a primary care drug linzess has over 3000 people promoting it. When it is all said and done 80 percent of volume will come from pcp. You need a partner and despite your so called stellar efficacy and no side effects no one is stepping up. No pain data and skewed side effect data equals no partner. We developed plecanatide and linaclotide and kept linzess. I'm gonna go with the MIT scientists who discovered GCC on this one..."

http://www.cafepharma.com/boards/threads/we-should-buy-synergy.583049/

👍️0

brownsfan407 9 년 전

I don't know the answer, but do you think they are happy with the price DEpreciation, under 11, it has been YEARS since it has been that low

👍️0

chemist99 9 년 전

IRWD:
% of Shares Held by Institutional & Mutual Fund Owners: 110%
% of Float Held by Institutional & Mutual Fund Owners: 112%
Number of Institutions Holding Shares: 163

SGYP:
% of Shares Held by Institutional & Mutual Fund Owners: 29%
% of Float Held by Institutional & Mutual Fund Owners: 32%
Number of Institutions Holding Shares: 90

source: Yahoo finance 07/22/15

👍️0

brownsfan407 9 년 전

% of Shares Held by All Insider and 5% Owners: 2 percent. surprisingly low. lots with their toes in the water, but no ringing endorsements

👍️0

brownsfan407 9 년 전

I can explain the price drop in facts, but I can't help you to understand it

👍️0

brownsfan407 9 년 전

Chemist, you the only one here? Looks like it

👍️0

brownsfan407 9 년 전

but our price is going up, I am sorry, which way is this price going? It is not going to be long before our price eclipses yours

👍️0

chemist99 9 년 전

Sgyp new short volume ~ 22 mill; - go figure ??

👍️0

brownsfan407 9 년 전

chemist, short up to 17 mill, too bad you can't use your moniker to reformulate this drug into something better, but then again, what chemistry do you need to use a virus?

👍️0

brownsfan407 9 년 전

hot 6 page found in nature thing working for you? I am having trouble with my pixels, did wedbush lower the target to 11? that's lower than the current price

👍️0

brownsfan407 9 년 전

6/15 was days before the phase 3 results. I bet some more shorted the 9 down to 8 to cover the earlier bad trade. We hire 2 more big guns today, and the pump articles and increasing price targets are like ants around a popsicle on a picnic, they are everywhere. Synergy will do ma secondary at 13, pay back the loan, and actually lower their share count, and knock off the interest

👍️0

chemist99 9 년 전

yes, IRWD short interest up to ~16 million shares, but SGYP up even more to about ~21.5 million shares per 06/15 :
http://www.nasdaq.com/symbol/sgyp/short-interest

the hedge funds must be in the business to lose money, I guess...

👍️0

brownsfan407 9 년 전

Chemist, Last SI up 2 million, are there folks betting on this going down. are you hedged? Sgyp set to double

👍️0

brownsfan407 9 년 전

How about your long position here? 1/3 the diarrhea rate for plecanatide, and filing NDA in November. Has to severely stunt the growth here. What is the adage, the market is forward looking? However, maybe you can clarify. The guy who took IRWD through the NDA process, does he still work for you?

👍️0

brownsfan407 9 년 전

In a few months the ticker symbol for Synergy may not exist, in a perfect world

👍️0

chemist99 9 년 전

No short no loss. Let's compare notes again in a few months. Enjoy it while it lasts??

👍️0

brownsfan407 9 년 전

what did you lose on the short? 6 bucks per share? and now, your long shares here are severely compromised. I would have some compassion for you if it were not for your past smugness and haughtiness

👍️0

brownsfan407 9 년 전

Game, set, match, plecanatide is clearly better. Cannot dispute the numbers, as the 600 rode the 89 percent gain

👍️0

chemist99 10 년 전

oh well, it served it's purpose, I suppose :)

👍️0

brownsfan407 10 년 전

check out lpcn, oral trt, NDA BY Q3, pre-term birth PILL too. Low float monster

👍️0

chemist99 10 년 전

lol.

a little knowledge can be a dangerous thing.

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Ironwood Pharmaceuticals Inc (IRWD)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

IRWD 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

IRWD Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Ironwood Pharmaceuticals Inc (IRWD) 뉴스

Ironwood Pharmaceuticals Inc (IRWD)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

IRWD 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

IRWD Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기